Actively Recruiting
Comparing Dotinurad and Allopurinol Oral Treatments for Adults with Gout to Lower Serum Uric Acid Levels
Led by Crystalys Therapeutics · Updated on 2026-10-29
500
Participants Needed
119
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.
CONDITIONS
Brief Title
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Research Team
C
Clinical Trial Lead
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here